AstraZeneca PLC is a global, science-led biopharmaceutical company specializing in the discovery, development, and commercialization of prescription medicines, particularly in Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology sectors. Headquartered in Cambridge, UK, AstraZeneca operates in over 100 countries, serving millions of patients worldwide with innovative medicines. Since its registration in the EU Transparency Register on 28 May 2020, AstraZeneca has actively engaged with EU institutions on a broad range of topics including healthcare, pharmaceutical policy, research and development, trade, sustainability, environment, public health, industrial policy, and intellectual property.
The company’s EU lobbying activities are conducted primarily through its Brussels office and focus on influencing policy frameworks that align with its business and scientific goals. AstraZeneca employs a dedicated team of lobbyists (3.45 full-time equivalents as of 2023) who maintain accreditation with the European Parliament to facilitate direct engagement with policymakers. The firm has held multiple high-level meetings with the European Commission (8 meetings reported in 2023) to advocate on its key issues.
AstraZeneca emphasizes transparency and ethical standards in its interactions, adhering to global transparency codes and regulations such as the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code. The company discloses payments and transfers of value made to healthcare providers and organizations to ensure confidence in the impartiality of medical recommendations and maintain compliance with international standards.
Financially, AstraZeneca has reported annual lobbying expenditures ranging from €700,000 to €799,999 in 2023, reflecting a significant investment in influencing EU policy. The company’s lobbying efforts are part of a broader strategy to shape regulatory and policy environments favorable to innovation and patient access to medicines.
